Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio

NEW YORK, March 10, 2023 /PRNewswire/ -- The diffuse large B-cell lymphoma (DLBCL) therapeutics market size is forecast to grow by USD 2,061.88 million between 2022 and 2027, and the growth momentum will accelerate at a CAGR of 7.96% during the forecast period. The number of regulatory approvals for therapeutics for patients with relapsed or refractory DLBCL is increasing. For instance, in November 2020, ADC Therapeutics SA announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the US Food and Drug Administration (FDA). Many such regulatory approvals are driving the growth of the market. For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample

Regional Analysis

By region, the global diffuse large B-cell lymphoma (DLBCL) therapeutics market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America will account for 46% of market growth during the forecast period. The increasing prevalence of various cancer types, including DLBCL is driving the growth of the diffuse large B-cell lymphoma (DLBCL) therapeutics market in North America. The increasing geriatric population in the region is another factor propelling the growth of the regional market.

Company Profiles

The diffuse large B-cell lymphoma (DLBCL) therapeutics market report includes information on the key products and recent developments of leading vendors, including:

• AbbVie Inc. - The company offers diffuse large b-cell lymphoma therapeutics such as DuoBody CD3xCD20.
• Bayer AG - The company offers diffuse large b-cell lymphoma therapeutics such as surgical resection.
• BeiGene Ltd. - The company offers diffuse large b-cell lymphoma therapeutics such as BTK Inhibitor BGB 3111.
• Bristol Myers Squibb Co. - The company offers diffuse large b-cell lymphoma therapeutics such as lymphodepleting chemotherapy.

Market Dynamics

The growth of the market is driven by factors such as the growing geriatric population, increasing incidence of DLBCL, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL. However, the high cost of DLBCL treatment will hinder the growth of the market.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share among others. Request a Sample

Market Segmentation

• By application, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
• By product, the market is segmented into small molecules and biologics.
• By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Why Buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio – Buy the Report!

Related Reports:

• The bispecific antibodies for cancer market is estimated to grow at a CAGR of 8.82% between 2022 and 2027. The size of the market is forecast to increase by USD 400.72 million. The increasing prevalence of cancer is notably driving the market growth, although factors such as the high cost of drugs may impede the market growth.
• The gene therapy market is estimated to grow at a CAGR of 19.91% between 2022 and 2027. The size of the market is forecast to increase by USD 4,613.9 million. The increase in special drug designations is notably driving the cell and gene therapy market growth, although factors such as the high treatment cost may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging
technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to
Technavio Insights

What are the key data covered in this diffuse large B-cell lymphoma (DLBCL) therapeutics market report?

• CAGR of the market during the forecast period.
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the size of the diffuse large B-cell lymphoma (DLBCL) therapeutics market and its contribution to the parent market.
• Accurate predictions about upcoming trends and changes in consumer behavior.
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW).
• A thorough analysis of the market's competitive landscape and detailed information about vendors.
• Comprehensive analysis of factors that will challenge the growth of diffuse large B-cell lymphoma (DLBCL) therapeutics market vendors.

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 - 2021 ($ million)

• 4.2 Application Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ million)

• 4.3 Product Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Application

• 6.1 Market segments 
• Exhibit 30: Chart on Application - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Application - Market share 2022-2027 (%)

• 6.2 Comparison by Application 
• Exhibit 32: Chart on Comparison by Application
• Exhibit 33: Data Table on Comparison by Application

• 6.3 Hospital pharmacy - Market size and forecast 2022-2027
• Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

• 6.4 Retail pharmacy - Market size and forecast 2022-2027
• Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

• 6.5 Online pharmacy - Market size and forecast 2022-2027
• Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)

• 6.6 Others - Market size and forecast 2022-2027
• Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 6.7 Market opportunity by Application 
• Exhibit 50: Market opportunity by Application ($ million)
• Exhibit 51: Data Table on Market opportunity by Application ($ million)

7 Market Segmentation by Product

• 7.1 Market segments 
• Exhibit 52: Chart on Product - Market share 2022-2027 (%)
• Exhibit 53: Data Table on Product - Market share 2022-2027 (%)

• 7.2 Comparison by Product 
• Exhibit 54: Chart on Comparison by Product
• Exhibit 55: Data Table on Comparison by Product

• 7.3 Small molecules - Market size and forecast 2022-2027
• Exhibit 56: Chart on Small molecules - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Small molecules - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Small molecules - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Small molecules - Year-over-year growth 2022-2027 (%)

• 7.4 Biologics - Market size and forecast 2022-2027
• Exhibit 60: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Chart on Biologics - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Biologics - Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by Product 
• Exhibit 64: Market opportunity by Product ($ million)
• Exhibit 65: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 67: Chart on Market share by geography 2022-2027 (%)
• Exhibit 68: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.10 Canada - Market size and forecast 2022-2027
• Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.11 China - Market size and forecast 2022-2027
• Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 107: Market opportunity by geography ($ million)
• Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 109: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 111: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 113: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 114: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 115: AbbVie Inc. - Overview
• Exhibit 116: AbbVie Inc. - Product / Service
• Exhibit 117: AbbVie Inc. - Key news
• Exhibit 118: AbbVie Inc. - Key offerings

• 12.4 Amgen Inc. 
• Exhibit 119: Amgen Inc. - Overview
• Exhibit 120: Amgen Inc. - Product / Service
• Exhibit 121: Amgen Inc. - Key offerings

• 12.5 Bayer AG 
• Exhibit 122: Bayer AG - Overview
• Exhibit 123: Bayer AG - Business segments
• Exhibit 124: Bayer AG - Key news
• Exhibit 125: Bayer AG - Key offerings
• Exhibit 126: Bayer AG - Segment focus

• 12.6 BeiGene Ltd. 
• Exhibit 127: BeiGene Ltd. - Overview
• Exhibit 128: BeiGene Ltd. - Business segments
• Exhibit 129: BeiGene Ltd. - Key offerings
• Exhibit 130: BeiGene Ltd. - Segment focus

• 12.7 Bristol Myers Squibb Co. 
• Exhibit 131: Bristol Myers Squibb Co. - Overview
• Exhibit 132: Bristol Myers Squibb Co. - Product / Service
• Exhibit 133: Bristol Myers Squibb Co. - Key news
• Exhibit 134: Bristol Myers Squibb Co. - Key offerings

• 12.8 Celltrion Healthcare Co. Ltd. 
• Exhibit 135: Celltrion Healthcare Co. Ltd. - Overview
• Exhibit 136: Celltrion Healthcare Co. Ltd. - Product / Service
• Exhibit 137: Celltrion Healthcare Co. Ltd. - Key offerings

• 12.9 CTI BioPharma Corp. 
• Exhibit 138: CTI BioPharma Corp. - Overview
• Exhibit 139: CTI BioPharma Corp. - Product / Service
• Exhibit 140: CTI BioPharma Corp. - Key offerings

• 12.10 Erytech Pharma SA 
• Exhibit 141: Erytech Pharma SA - Overview
• Exhibit 142: Erytech Pharma SA - Product / Service
• Exhibit 143: Erytech Pharma SA - Key offerings

• 12.11 F. Hoffmann La Roche Ltd. 
• Exhibit 144: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 145: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 146: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 147: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 148: F. Hoffmann La Roche Ltd. - Segment focus

• 12.12 GlaxoSmithKline Plc 
• Exhibit 149: GlaxoSmithKline Plc - Overview
• Exhibit 150: GlaxoSmithKline Plc - Business segments
• Exhibit 151: GlaxoSmithKline Plc - Key offerings
• Exhibit 152: GlaxoSmithKline Plc - Segment focus

• 12.13 Johnson and Johnson 
• Exhibit 153: Johnson and Johnson - Overview
• Exhibit 154: Johnson and Johnson - Business segments
• Exhibit 155: Johnson and Johnson - Key news
• Exhibit 156: Johnson and Johnson - Key offerings
• Exhibit 157: Johnson and Johnson - Segment focus

• 12.14 Merck and Co. Inc. 
• Exhibit 158: Merck and Co. Inc. - Overview
• Exhibit 159: Merck and Co. Inc. - Business segments
• Exhibit 160: Merck and Co. Inc. - Key news
• Exhibit 161: Merck and Co. Inc. - Key offerings
• Exhibit 162: Merck and Co. Inc. - Segment focus

• 12.15 Novartis AG 
• Exhibit 163: Novartis AG - Overview
• Exhibit 164: Novartis AG - Business segments
• Exhibit 165: Novartis AG - Key offerings
• Exhibit 166: Novartis AG - Segment focus

• 12.16 Pfizer Inc. 
• Exhibit 167: Pfizer Inc. - Overview
• Exhibit 168: Pfizer Inc. - Product / Service
• Exhibit 169: Pfizer Inc. - Key news
• Exhibit 170: Pfizer Inc. - Key offerings

• 12.17 Spectrum Pharmaceuticals Inc. 
• Exhibit 171: Spectrum Pharmaceuticals Inc. - Overview
• Exhibit 172: Spectrum Pharmaceuticals Inc. - Product / Service
• Exhibit 173: Spectrum Pharmaceuticals Inc. - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 174: Inclusions checklist
• Exhibit 175: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 176: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 177: Research methodology
• Exhibit 178: Validation techniques employed for market sizing
• Exhibit 179: Information sources

• 13.5 List of abbreviations 
• Exhibit 180: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio